Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Pancreatic ductal adenocarcinoma (PDAC), as the most frequent form of pancreatic malignancy, still is associated with a dismal prognosis. Due to its late detection, most patients are ineligible for surgery, and chemotherapeutic options are limited. Tumor heterogeneity and a characteristic structure...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabacaoglu, Derya, Ciecielski, Katrin J., Ruess, Dietrich A., Algül, Hana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104627/
https://www.ncbi.nlm.nih.gov/pubmed/30158932
http://dx.doi.org/10.3389/fimmu.2018.01878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104627/
https://www.ncbi.nlm.nih.gov/pubmed/30158932
http://dx.doi.org/10.3389/fimmu.2018.01878

Ejemplares similares